Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
5.2
Journals
Cancers
Special Issues
Stereotactic Radiotherapy in Tumor Ablation (Volume II)
share announcement

Stereotactic Radiotherapy in Tumor Ablation (Volume II)

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".

Deadline for manuscript submissions: 31 December 2024 | Viewed by 575

Special Issue Editors

Dr. Rémy Kinj

E-Mail Website
Guest Editor
Service of Radiation Oncology, Department of Oncology, Lausanne University Hospital, 1010 Lausanne, Switzerland
Interests: stereotactic body radiotherapy; re-irradiation; lattice radiotherapy; thoracic radiotherapy
Special Issues, Collections and Topics in MDPI journals
Prof. Dr. Jean Bourhis

E-Mail Website
Guest Editor
Department of Radiation Oncology, Lausanne University Hospital, CH-1205 Lausanne, Switzerland
Interests: head and neck radiotherapy; flash radiotherapy; stereotactic body radiotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

We would like to cordially invite you to contribute to the collection of articles related to "Stereotactic Radiotherapy in Tumor Ablation".

In the last decade, we have seen a growing interest in oncology for stereotactic body radiotherapy (SBRT), which appears as a highly effective, non-invasive, and safe tumor ablative treatment.

SBRT is building on major improvements in delivery achieved by intensity-modulated and image-guided radiotherapy, which now permit safe ablative doses of radiation to be delivered. SBRT is increasingly being used to treat a variety of cancers, including primary tumors as well as metastases in a wide range of locations (brain, bone, lung, prostate, liver, etc.).

Accumulated clinical evidence is growing over time, with efficacy and safety having being demonstrated in randomized clinical trials.

This collection of articles aims to provide a comprehensive and broad overview of the use of SBRT in the central nervous system, head and neck, thorax, abdomen, and pelvis, as well as its use in re-irradiation or metastatic and oligometastatic settings. Discussions on the technical evolutions, biological background, new developments, and potential limitations are encouraged. The remarkable complementarity of SBRT with systemic treatments is also important to emphasize.

Our goal is to create a reliable and updated source of information for all physicians and oncologists and improve cancer care through the use of this cutting-edge technology.

We look forward to receiving your contributions to this Special Issue of the journal Cancers.

Dr. Rémy Kinj
Prof. Dr. Jean Bourhis
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • SBRT
  • stereotactic body radiotherapy
  • SABR
  • stereotactic ablative radiotherapy
  • re-irradiation
  • oligometastasis
  • local therapy

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

13 pages, 1000 KiB  
Article
Long-Term Results of Stereotactic Radiotherapy in Patients with at Least 10 Brain Metastases at Diagnosis
by Rémy Kinj, Andreas Felix Hottinger, Till Tobias Böhlen, Mahmut Ozsahin, Véronique Vallet, Vincent Dunet, Hasna Bouchaab, Solange Peters, Constantin Tuleasca, Jean Bourhis and Luis Schiappacasse
Cancers 2024, 16(9), 1742; https://doi.org/10.3390/cancers16091742 - 29 Apr 2024
Viewed by 477
Abstract
Purpose: to evaluate an SRT approach in patients with at least 10 lesions at the time of BM initial diagnosis. Methods: This is a monocentric prospective cohort of patients treated by SRT, followed by a brain MRI every two months. Subsequent SRT could [...] Read more.
Purpose: to evaluate an SRT approach in patients with at least 10 lesions at the time of BM initial diagnosis. Methods: This is a monocentric prospective cohort of patients treated by SRT, followed by a brain MRI every two months. Subsequent SRT could be delivered in cases of new BMs during follow-up. The main endpoints were local control rate (LCR), overall survival (OS), and strategy success rate (SSR). Acute and late toxicity were evaluated. Results: Seventy patients were included from October 2014 to January 2019, and the most frequent primary diagnosis was non-small-cell lung cancer (N = 36, 51.4%). A total of 1174 BMs were treated at first treatment, corresponding to a median number of 14 BMs per patient. Most of the patients (N = 51, 72.6%) received a single fraction of 20–24 Gy. At 1 year, OS was 62.3%, with a median OS of 19.2 months, and SSR was 77.8%. A cumulative number of 1537 BM were treated over time, corresponding to a median cumulative number of 16 BM per patient. At 1-year, the LCR was 97.3%, with a cumulative incidence of radio-necrosis of 2.1% per lesion. Three patients (4.3%) presented Grade 2 toxicity, and there was no Grade ≥ 3 toxicity. The number of treated BMs and the treatment volume did not influence OS or SSR (p > 0.05). Conclusions: SRT was highly efficient in controlling the BM, with minimal side effects. In this setting, an SRT treatment should be proposed even in patients with ≥10 BMs at diagnosis. Full article
(This article belongs to the Special Issue Stereotactic Radiotherapy in Tumor Ablation (Volume II))
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop